Compare HIHO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | VIVS |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | 9 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.9M |
| IPO Year | 2002 | N/A |
| Metric | HIHO | VIVS |
|---|---|---|
| Price | $0.82 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 80.7K | 67.3K |
| Earning Date | 03-02-2026 | 06-03-2026 |
| Dividend Yield | ★ 14.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $1.42 |
| 52 Week High | $2.21 | $5.30 |
| Indicator | HIHO | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 36.59 | 37.47 |
| Support Level | $0.77 | N/A |
| Resistance Level | $1.04 | $2.08 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 8.33 | 1.82 |
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.